Enoxaparin 40 mg SC

DRUG2 trials

Sponsors

The TIMI Study Group, Mayo Hospital Lahore

Conditions

Arterial ThrombosisCOVID-19Deep Venous ThrombosesLaparotomy PatientsVenous Thromboembolism

Phase 4

Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

CompletedNCT04409834

The TIMI Study GroupArterial Thrombosis, COVID-19, Venous Thromboembolism

Start: 2020-08-05End: 2022-03-10Updated: 2024-01-19

Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention

RecruitingNCT07243080

Mayo Hospital LahoreDeep Venous Thromboses, Laparotomy Patients

Start: 2025-10-10End: 2025-11-15Target: 212Updated: 2025-11-21

Related Papers

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

Circulation2022-08-2981 citations

Platelet Reactivity and Coagulation Markers in Patients with COVID-19

Advances in Therapy2021-06-0430 citations